Health Sciences Institute, Erciyes University, Kayseri, Turkey
Department of Medical Biochemistry, Faculty of Medicine, Erciyes University, Kayseri, Turkey
Turk J Med Sci. 2021 Jun 28;51(3):1354-1359. doi: 10.3906/sag-2012-195.
BACKGROUND/AIM: Targeting the new and unique proteins is an important medical strategy for treating breast cancer. It is quite important to find out proteins that have a role in the development of cancer. Sirtuins (SIRT) are well related in different physiological activities and connected with cancer. We aimed to determine the effect of radiotherapy on SIRT1 and SIRT2, which have not been yet been clarified as a tumor suppressor or promoter.
Twenty-two women with nonmetastatic breast cancer enrolled in the study. Blood samples were taken before and after radiotherapy, soluble SIRT1 and SIRT2 levels were determined with ELISA kits.
There was no difference in SIRT1 levels before and after radiotherapy (p = 0.548). SIRT2 levels were significantly found to be decreased after radiotherapy (p = 0.042). There was a strong and positive correlation before radiotherapy (p < 0.001), and a moderate and positive correlation after radiotherapy (p = 0.007) between SIRT1 and SIRT2.
These results suggest that SIRT2 may provide a new strategy for follow-up of breast cancer treatment. Additionally, by emphasizing the importance of SIRT2 in breast cancer, it opens ways to provide grounds for the development of the next generation of SIRT2-specific radiotracers. Finally, the most important thing, in fact, the positive correlation between SIRT1 and SIRT2 both before and after radiotherapy, appears to be clear evidence suggesting more oncogenic roles of sirtuins.
背景/目的:针对新的独特蛋白是治疗乳腺癌的重要医学策略。发现与癌症发展有关的蛋白质非常重要。Sirtuins(SIRT)在不同的生理活动中密切相关,并与癌症有关。我们旨在确定尚未被明确为肿瘤抑制因子或促进因子的 SIRT1 和 SIRT2 的放射治疗效应。
22 名患有非转移性乳腺癌的女性入组本研究。在放疗前后采集血样,用 ELISA 试剂盒测定可溶性 SIRT1 和 SIRT2 水平。
放疗前后 SIRT1 水平无差异(p = 0.548)。放疗后 SIRT2 水平显著降低(p = 0.042)。放疗前两者之间存在强正相关(p < 0.001),放疗后存在中度正相关(p = 0.007)。
这些结果表明,SIRT2 可能为乳腺癌治疗的随访提供新策略。此外,通过强调 SIRT2 在乳腺癌中的重要性,为开发下一代 SIRT2 特异性放射性示踪剂提供了依据。最后,事实上,放疗前后 SIRT1 和 SIRT2 之间的正相关似乎清楚地表明了 sirtuins 的更致癌作用。